An anonymous reader quotes a report from NPR: For the first time, doctors in the U.S. have used the powerful gene-editing technique CRISPR to try to treat a patient with a genetic disorder. "It is just amazing how far things have come," says Victoria Gray, 34, of Forest, Miss. "It is wonderful," she told NPR in an exclusive interview after undergoing the landmark treatment for sickle cell disease. Gray is the first patient ever to be publicly identified as being involved in a study testing the use of CRISPR for a genetic disease. "I always had hoped that something will come along," she says from a hospital bed at the Sarah Cannon Research Institute in Nashville, Tenn., where she received an infusion of billions of genetically modified cells. "It's a good time to get healed." But it probably will take months, if not years, of careful monitoring of Gray and other patients before doctors know whether the treatment is safe and how well it might be helping patients. "For the study, doctors are using cells taken from patients' own bone marrow that have been genetically modified with CRISPR to make them produce a protein that is usually only made by fetuses and by babies for a short time following birth," the report adds. "The hope is this protein will compensate for the defective protein that causes sickle cell disease and will enable patients to live normally for the rest of their lives."

Scientists at the University of California San Diego have created a contact lens, controlled by eye movements, that can zoom in if you blink twice. "In the simplest of terms, the scientists measured the electrooculographic signals generated when eyes make specific movements (up, down, left, right, blink, double blink) and created a soft biomimetic lens that responds directly to those electric impulses," reports CNET. "The lens created was able to change its focal length depending on the signals generated." From the report: Incredibly, the lens works regardless of whether the user can see or not. It's not about the sight, it's about the electricity produced by specific movements. The researchers believe this innovation could be used in "visual prostheses, adjustable glasses, and remotely operated robotics in the future."

CNN tells the story of a new medical breakthrough for Keven Walgamott, who 17 years ago lost one hand and part of his forearm in an electrical accident. Now, Walgamott can use his thoughts to tell the fingers of his bionic hand to pick up eggs and grapes. The prosthetic arm he tested also allowed Walgamott to feel the objects he grasped. A biomedical engineering team at the University of Utah created the "LUKE Arm," named in honor of the robotic hand Luke Skywalker obtains in "Star Wars: The Empire Strikes Back" after Darth Vader slices off his hand with a lightsaber.

A new study published Wednesday in the journal Science Robotics explained how the arm revived the sensation of touch for Walgamott. The University of Chicago and the Cleveland Clinic were also involved in the study... The LUKE Arm sends signals to the brain in order to mimic the way a human hand can feel and sense information about an object, like whether it's soft, hard, lightweight or heavy. "We changed the way we are sending that information to the brain so that it matches the human body..." said Jacob George, study author and biomedical engineering doctoral student at the University of Utah. "We're making more biologically realistic signals..."

Utah Emeritus Distinguished Professor Richard A. Normann invented the Utah Slanted Electrode Array, a grouping of 100 microelectrodes and wires implanted in the forearm's nerves and connected to an external computer. The array was able to read signals from the nerves remaining in Walgamott's arm while the computer converted them into digital signals. The signals would act like messages for the arm to move. But in order to be successful, things would have to work the opposite way as well, meaning the LUKE Arm would need to be able to sense objects and understand the necessary pressure needed to hold them. Sensors in the hand of the LUKE Arm send signals through the Array to the existing nerves, communicating the feeling the hand should be receiving when it touches something.
Created by DEKA R&D (founded by Segway inventor Dean Kamen), the LUKE arm "was in development for 15 years and is composed of metal motors with a clear silicon overlay that mimics skin," the article points out.

While it currently draws power from an external battery (and is wired to a computer), they're working on creating a wireless version.

An anonymous reader quotes a report from The Verge: A new report from The Wall Street Journal shares some of the proposals for Saudi Arabia's biggest megaproject yet: a city built in the desert named Neom, where robots will outnumber humans and hologram teachers will educate genetically-enhanced students. These are only proposals, of course, dreamt up by American consulting firms like McKinsey and Boston Consulting who have no incentive to bring Saudi leaders down to Earth. But all the same, they give you a flavor of what trillions of dollars of oil wealth will do to your sense of proportion.

The whole Neom project is undeniably fascinating. It was first announced in 2017, with Saudi Arabia's de-facto leader, Crown Prince Mohammed bin Salman, saying he wants the city to attract the "world's greatest minds and best talents." According to planning documents reported by the WSJ, bin Salman "envisions Neom the largest city globally by GDP, and wanted to understand what he can get with up to 500 billion USD investment." The project is the flagpole of Saudi Arabia's plans to diversify the country's economy away from oil. MBS and other Saudi leaders known this source of revenue can't last forever, and they're keen to develop cities like Neom as new commercial hubs. As currently planned, Neom will occupy a region the size of Massachusetts. This will include a huge coastal urban sprawl; outlying towns and villages; advance manufacturing hubs in industries like biotech and robotics; and links with international shipping routes. Early building work has already begun, with facilities including a new airport and palace. Some of the key features of the city include cloud seeding to make it rain, dystopian surveillance to keep citizens safe, genetic engineering to increase human strength and IQ, robot cage fights and "maids," flying taxis, and even a fake moon that could perhaps be created by a fleet of drones or via live-streaming images from space.

The report notes that it's anyone's guess as to whether Neom will live up to its planners' dreams. What may hinder its success is Saudi Arabia's corruption, difficult legal system, and unappealing social norms. "Alcohol is banned; women's rights are restricted; and homosexuality is illegal," the report notes. There's also the sweltering weather that'll only get worse with climate change.

Lab-grown meat, first introduced to the world six years ago in the form of a $280,000 hamburger, could hit supermarket shelves at $10 a patty within two years, European start-ups told Reuters. From a report: Consumers concerned about climate change, animal welfare and their own health are fueling interest in so-called clean meat, with the number of associated business start-ups climbing from four at the end of 2016 to more than two dozen two years later, according to the Good Food Institute market researcher. Plant-based meat alternatives are also booming. Shares in Beyond Meat have more than tripled in price since its initial public offering in May. Beyond Meat and Impossible Foods each sell 100% plant-based meat alternatives to retailers and fast food chains across the United States.

And cultured meat grown from animal cells could be next on the mainstream menu, with producers eyeing regulatory approval as they improve the technology and reduce costs. It was Dutch start-up Mosa Meat's co-founder Mark Post who created the first "cultured" beef hamburger in 2013 at a cost of 250,000 euros ($280,400), funded by Google co-founder Sergey Brin, but Mosa Meat and Spain's Biotech Meats say that production costs have fallen dramatically since then. "The burger was this expensive in 2013 because back then it was novel science and we were producing at very small scale. Once production is scaled up, we project the cost of producing a hamburger will be around 9 euros," a Mosa Meat spokeswoman told Reuters, adding that it could ultimately become even cheaper than a conventional hamburger.

"Life's information-storage system is being adapted to handle massive amounts of information," reports Scientific American, reports Scientific American, calling it "an alternative to hard drives" and noting that DNA "is already routinely sequenced (read), synthesized (written to) and accurately copied with ease.

"DNA is also incredibly stable, as has been demonstrated by the complete genome sequencing of a fossil horse that lived more than 500,000 years ago. And storing it does not require much energy." But it is the storage capacity that shines. DNA can accurately stow massive amounts of data at a density far exceeding that of electronic devices. The simple bacterium Escherichia coli, for instance, has a storage density of about 10**19 bits per cubic centimeter, according to calculations published in 2016 in Nature Materials by George Church of Harvard University and his colleagues. At that density, all the world's current storage needs for a year could be well met by a cube of DNA measuring about one meter on a side.

The prospect of DNA data storage is not merely theoretical. In 2017, for instance, Church's group at Harvard adopted CRISPR DNA-editing technology to record images of a human hand into the genome of E. coli, which were read out with higher than 90 percent accuracy. And researchers at the University of Washington and Microsoft Research have developed a fully automated system for writing, storing and reading data encoded in DNA. A number of companies, including Microsoft and Twist Bioscience, are working to advance DNA-storage technology... DNA bar coding is now being used to dramatically accelerate the pace of research in fields such as chemical engineering, materials science and nanotechnology.

Long-time Slashdot reader tomhath shares some big bacteria news from Harvard Medical School: Researchers from Joslin Diabetes Center determined Veillonella metabolizes lactic acid produced by exercise and converts it into propionate, a short chain fatty acid. The human body then utilizes that propionate to improve exercise capacity...

"It creates this positive feedback loop. The host is producing something that this particular microbe favors. Then in return, the microbe is creating something that benefits the host," Aleksandar D. Kostic Ph.D. says. "This is a really important example of how the microbiome has evolved ways to become this symbiotic presence in the human host."
By Friday, CNBC was reporting their research "could lead to a probiotic-like supplement that 'regular joes' could use to enhance their performance in a few years." "The future of fitness is here and it's something that we're rapidly developing," Jonathan Scheiman, former Harvard postdoctoral fellow and CEO and co-founder of FitBiomics, tells CNBC Make It. "We want to translate this into consumer products to promote health and wellness [to the masses]..." [The researchers] found the mice given Veillonella ran 13% longer on a treadmill compared to mice who were not given the bacteria. "It might not seem like a huge number, but I definitely think its biologically significant and certainly if you ask a marathon runner, if they could increase their running ability by 13% -- I think that they will be generally interested," Aleksandar Kostic, co-author of the study and an assistant professor of microbiology at the Joslin Diabetes Center tells CNBC Make It.

An anonymous reader quotes a report from TechCrunch: Elizabeth Holmes, the founder of the now-defunct biotech unicorn Theranos, will face trial in federal court next summer with penalties of up to 20 years in prison and millions of dollars in fines. Jury selection will begin July 28, 2020, according to U.S. District Judge Edward J. Davila, who announced the trial will commence in August 2020 in a San Jose federal court Friday morning. Holmes and former Theranos president Ramesh "Sunny" Balwani were indicted by a grand jury last June with 11 criminal charges in total. Two of those charges were conspiracy to commit wire fraud (against investors, and against doctors and patients). The remaining nine are actual wire fraud, with amounts ranging from the cost of a lab test to $100 million. Bloomberg says Holmes' legal team plans to argue that The Wall Street Journal's John Carreyrou "had an undue influence on federal regulators," and "went beyond reporting the Theranos story."

"The jury should be aware that an outside actor, eager to break a story, and portray the story as a work of investigative journalism, was exerting influence on the regulatory process in a way that appears to have warped the agencies' focus on the company and possibly biased the agencies' findings against it," her attorneys wrote, per Bloomberg. "The agencies' interactions with Carreyrou thus go to the heart of the government's case."

Ars Technica documents "a new breed of digital fraudsters" using a complicated scam to prey on white-collar job-seekers.

It involves setting up a fake job interview process and the promises of high-paying work: Like most successful cons, this one involved gaining the willing consent of its victim through some combination of greed, fear, or desperation... The recruiter was responding to the application I had submitted a day earlier for a remote-work tech writer position at a biotech firm... The following day, I logged onto Google Hangouts, properly dressed and groomed for the video chat I'd been preparing for. To my surprise, I learned that the interview would be conducted using Hangouts' text messaging service... After a long briefing about the company, its research, and the oncology treatments it was developing, Mark began the formal part of the interview by introducing himself as the assistant chief human resources officer of the company and describing the duties I'd be expected to fulfill...

But there were two questions that seemed out of place. They wanted to know which bank I used and whether it supported electronic deposits, a process in which you deposit checks by taking pictures of them with your Smartphone. It seemed like an odd thing to ask, but I told them that my bank did accept electronic deposits and moved on to the next question... Within a few minutes of submitting my answers, Mark informed me that I'd passed the interview and would receive a formal offer to work from my home as a copywriter/proofreader. My pay would be $45/hour during my one-week training and evaluation period, stepping up to $50/hour when I became an employee.
The scammer even assigned fake work -- editing a monograph on cancer treatment protocols following the company's style guide -- while casually promising to send along a check to purchase the necessary high-end equipment for the job. The job-seeker was instructed to scan their deposit receipt and then email the image to the scammers. (And the check was issued from a private Catholic girls' school in Southern California -- while the job-seeker was instructed to make their purchase from "preferred vendors.")

Though the scam ultimately wasted 'more than two days worth of my time," at least it revealed something about today's online job sites. "After some more digging, it quickly became apparent that the False Flag Employer scam I nearly fell for is an increasingly common type of cybercrime."

elainerd (Slashdot reader #94,528) shares an article from The Next Web: Scientists from Cornell University have successfully constructed DNA-based machines with incredibly life-like capabilities. These human-engineered organic machines are capable of locomotion, consuming resources for energy, growing and decaying, and evolving. Eventually they die.

That sure sounds a lot like life, but Dan Luo, professor of biological and environmental engineering in the College of Agriculture and Life Sciences at Cornell, who worked on the research, says otherwise. He told The Stanford Chronicle, "We are introducing a brand-new, lifelike material concept powered by its very own artificial metabolism. We are not making something that's alive, but we are creating materials that are much more lifelike than have ever been seen before." Just how lifelike? According to the research they're on par with biologically complex organisms such as mold.... "Dynamic biomaterials powered by artificial metabolism could provide a previously unexplored route to realize 'artificial' biological systems with regenerating and self-sustaining characteristics."

Basically, the Cornell team grew their own robots using a DNA-based bio-material, observed them metabolizing resources for energy, watched as they decayed and grew, and then programmed them to race against each other... Lead author on the team's paper, Shogo Hamada, told The Stanford Chronicle that "ultimately, the system may lead to lifelike self-reproducing machines."

An anonymous reader quotes CNN: The first medical device to treat childhood attention deficit hyperactivity disorder, or ADHD, was OK'd Friday by the U.S. Food and Drug Administration. Designated for children ages 7 to 12 who are not currently on medication for the disorder, the device delivers a low-level electrical pulse to the parts of the brain responsible for ADHD symptoms.... The pocket-sized device is connected by wire to a small adhesive patch placed on the child's forehead above the eyebrows. Designed to be used at home while sleeping, it delivers a "tingling" electrical stimulation to branches of the cranial nerve that delivers sensations from the face to the brain.

A clinical trial of 62 children showed that the Monarch external Trigeminal Nerve Stimulation System increases activity in the regions of the brain that regulate attention, emotion and behavior, all key components of ADHD. Compared to a placebo, children using the device had statistically significant improvement in their ADHD symptoms, the FDA said, although it could take up to four weeks to see improvement. Authors of the clinical trial called for additional research to examine if the response to treatment will last over time, and its potential impact on brain development with prolonged use....

The device was previously approved for the treatment of epilepsy and depression in Europe and Canada. Studies at UCLA found the stimulation decreased seizure activity by inhibiting overactive neurons in one section of the brain, while stimulating blood flow in the areas that control mood, attention and executive function.
CNN reports that the manufacturer's web site says the device costs around $1,000 -- and is not covered by insurance.

The FDA added that common side effects could include headache, teeth clenching, and trouble sleeping (as well as fatigue and sleepiness).

Since 2008, a $65 million program has been designing a sophisticated new "ignition interlock" system that would only allows cars to start if it detects that the driver is sober, the Washington Post reports: What's different -- perhaps even revolutionary -- is that the built-in ignition interlock would make an instantaneous and precise reading of every driver's blood alcohol content (BAC) level when the driver attempts to start the vehicle. Eventually, the device could become standard equipment, just like air bags. The device would take BAC samples in one of two ways. A breath-based system would gather a whiff of a driver's ambient breath. A touch-based system would analyze the touch of a driver's finger, perhaps from a vehicle's starter button or the steering wheel....

Officials behind the public-private effort to develop the technology -- known as the Driver Alcohol Detection System for Safety (DADSS) -- say the device will be ready for commercial fleets next year. Virginia's Department of Motor Vehicles became the first state agency to use it in its fleet last year, and a private company, James River Transportation, is road-testing them in its fleet of Ford Flex crossovers.... . Advocates say that if their work is successful, such a device -- which requires understanding complexities involving the science of biology, spectroscopy, electrical engineering, consumer behavior and even politics -- could save an estimated 10,000 lives a year.
"We intend to release by the end of 2020 a breath-based device for use in fleet applications and as a dealer-installed accessory," says the president of Automotive Coalition for Traffic Safety, which represents 17 automakers.

He tells the Post that the interlock devices now available are zero-tolerance -- "if any amount of alcohol is present, they will lock you out" -- and "are very difficult to use... Even people who use them regularly and are experienced in using them typically fail to provide a sufficient breath sample about 30 percent of the time... The other problem with those mouthpieces [besides some drivers seeing them as uncomfortable or intrusive] is they're plastic and you can only use them about five times... And then, the technology has to be recalibrated roughly every year, dependent upon usage. If you use it more, you have to calibrate it more frequently."

But with the new devices, "you simply sit in driver's seat and breathe normally. That's all that's required. There is no mouthpiece... We want to make a very precise very accurate measurement within a third of a second."

"A second male birth control pill succeeded in preliminary testing, suggesting that a new form of contraception may eventually exist," reports Time: The new pill, which works similarly to female contraception, passed initial safety tests and produced hormone responses consistent with effective birth control in 30 men, according to research presented by the Los Angeles Biomedical Research Institute and the University of Washington at the Endocrine Society's annual meeting. (The study has not yet been published in a peer-reviewed journal.) It's early days for the drug -- which has not yet been submitted for approval by the Food and Drug Administration (FDA) -- but co-principal investigator Dr. Christina Wang, lead researcher at LA BioMed, says it's an important step toward effective, reversible male hormonal contraception....

Unlike a 2016 male birth control trial that famously stopped enrolling volunteers early because so many men complained of side effects, none of the men experienced serious problems, and no one stopped taking the drug because of side effects.

An anonymous reader quotes the Harvard School of Public Health: Drug-resistant strains of gonorrhea, salmonella, Escherichia coli (E. coli) and many other disease-causing agents are flourishing around the world, and the consequences are disastrous -- at least 700,000 people die globally as a result of antimicrobial resistance (AMR) annually, according to a 2016 review on antimicrobial resistance commissioned by former UK Prime Minister David Cameron. It's a perilous situation, but several new studies from researchers at Harvard T.H. Chan School of Public Health indicate that an important tool in the fight against AMR already exists: vaccines.

The Proceedings of the National Academy of Sciences recently devoted a special feature section to examine the role vaccines can play in stemming the tide of antimicrobial resistance. In general terms, vaccinations can help lessen the burden in two ways: First, they can protect against the direct transmission of drug-resistant infections. Second, they can lessen the chances of someone getting sick, which in turn reduces the likelihood that he or she will be prescribed antibiotics or other medications. The fewer medications someone takes, the less likely it is that microbes will evolve resistance to the drugs.

NBC News reports on how microbiologist Gerry Quinn "followed up on some folklore his family had passed on to him." Old timers insisted that the dirt in the vicinity of a nearly 1,500-year-old church in County Fermanagh in Northern Ireland, an area once occupied by the Druids, had almost miraculous curative powers.... "Here in the western fringes of Ireland there is still a tradition of having this folk cure," Quinn told NBC News. "We can look at it and see maybe it's just superstition -- or we can actually investigate and ask, 'is there anything in the soil that produces antibiotics...?'"

Once Quinn and his team decided to focus on the Irish soil, they narrowed their search to a specific type of bacteria, called Streptomyces, because other strains of this bacteria have led to the development of 75 percent of existing antibiotics, Quinn said. The bacteria was discovered by a team based at Swansea University Medical School, made up of researchers from Wales, Brazil, Iraq and Northern Ireland. The researchers first tried the newly discovered strain of Streptomyces on some garden variety bacteria. In their petri dish experiment, "it knocked them out," Quinn said. "Then we thought we'd take it one step further and find some multi-resistant organisms."

The bacteria in the experiment killed four out of the top six organisms that are resistant to antibiotics, including MRSA. "It's quite surprising," said Quinn... "The lesson is, some of the cures are right underneath your feet."
Vaughn Cooper, an evolutionary geneticist/microbiologist at the University of Pittsburgh's School of Medicine, tells NBC that more research is needed before this yields a super-antibiotic -- but "it's a cool discovery."

The World Health Organization has named antibiotic resistance as one of 2019's ten top public health threats.

"The first genetically-modified animal for human consumption could be arriving in grocery stores across the United States as early as next year." Long-time Slashdot reader tomhath tipped us off to Indiana Public Media's report on AquaBounty Technologies: AquaBounty will produce a GMO salmon that CEO Ron Stotish says will grow faster than freshwater-raised fish. "It does so because we've given it the ability, using the same biological process that regulates growth in the unmodified salmon, to grow about twice as fast reaching market rate about half the time," Stotish says. The technology has been around since the 1990s, but it took until 2015 to receive approval from the U.S. Food and Drug Administration, due to concerns about people eating genetically-modified animals. The genetic makeup of the biotech fish takes a growth-hormone regulatory gene from the Pacific Chinook salmon with a promoter gene from an ocean pout and puts it into the genome of an Atlantic salmon. The result causes for the growth hormone to remain on leading to faster growth rate than non GMO salmon.

The modified fish is able to grow to market size using 25 percent less feed than the traditional salmon, increasing cost efficiency... Stotish says his operation causes less harm than traditional fish farming. "We're not using coastal waterways, we're not putting antibiotics and medications into the water," Stotish says. "Our fish are in a controlled environment, we don't need antibiotics, we don't have to treat for sea lice."
The company says that every year Americans consume about 350,000 tons of Atlantic salmon -- more than 95% of which has to be imported.

An anonymous reader shares a report: Despite all her alleged crimes, Elizabeth Holmes, the former CEO of the biotech company Theranos, can rest assured she still has someone who'll go to bat for her. At a panel discussion on growing startup ecosystems at the Montgomery Summit yesterday, Bloomberg reporter Sarah McBride asked Tim Draper -- a venture capitalist, enthusiastic Bitcoin supporter, and one of Theranos' first investors -- whether he would back Holmes again. Draper responded to the question by saying, "I'd back her as chief science officer, not CEO. Good question."

Joe_NoOne (Slashdot reader #48,818) shares this update from Nature: The DNA of life on Earth naturally stores its information in just four key chemicals -- guanine, cytosine, adenine and thymine, commonly referred to as G, C, A and T, respectively. Now scientists have doubled this number of life's building blocks, creating for the first time a synthetic, eight-letter genetic language that seems to store and transcribe information just like natural DNA.

In a study published on 22 February in Science, a consortium of researchers led by Steven Benner, founder of the Foundation for Applied Molecular Evolution in Alachua, Florida, suggests that an expanded genetic alphabet could, in theory, also support life. "It's a real landmark," says Floyd Romesberg, a chemical biologist at the Scripps Research Institute in La Jolla, California. The study implies that there is nothing particularly "magic" or special about those four chemicals that evolved on Earth, says Romesberg. "That's a conceptual breakthrough," he adds... Benner says that the work shows that life could potentially be supported by DNA bases with different structures from the four that we know, which could be relevant in the search for signatures of life elsewhere in the Universe...

The researchers call the resulting eight-letter language 'hachimoji' after the Japanese words for 'eight' and 'letter'. The additional bases are each similar in shape to one of the natural four, but have variations in their bonding patterns. The researchers then conducted a series of experiments that showed that their synthetic sequences shares properties with natural DNA that are essential for supporting life... Benner's group previously showed that strands of DNA that included Z and P were better at binding to cancer cells than sequences with just the standard four bases. And Benner has set up a company which commercialises synthetic DNA for use in medical diagnostics.

A new adsorbent material "soaks up uranium from seawater, leaving interfering ions behind," reports the ACS's Chemical & Engineering News, in an article shared by webofslime: The world's oceans contain some 4 billion metric tons of dissolved uranium. That's roughly 1,000 times as much as all known terrestrial sources combined, and enough to fuel the global nuclear power industry for centuries. But the oceans are so vast, and uranium's concentration in seawater is so low -- roughly 3 ppb -- that extracting it remains a formidable challenge... Researchers have been looking for ways to extract uranium from seawater for more than 50 years...

Nearly 20 years ago, the Japan Atomic Energy Agency (JAEA) confirmed that amidoxime-functionalized polymers could soak up uranium reliably even under harsh marine conditions. But that type of adsorbent has not been implemented on a large scale because it has a higher affinity for vanadium than uranium. Separating the two ions raises production costs. Alexander S. Ivanov of Oak Ridge National Laboratory, together with colleagues there and at Lawrence Berkeley National Laboratory and other institutions, may have come up with a solution. Using computational methods, the team identified a highly selective triazine chelator known as H2BHT that resembles iron-sequestering compounds found in bacteria and fungi.... H2BHT exhibits little attraction for vanadium but has roughly the same affinity for uranyl ions as amidoxime-based adsorbents do.

Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run. "Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution." From a report: "The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."

Richter cited Gilead Sciences' treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company's U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report. "GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients," the analyst wrote.